GB2528604A - Modulation of asymmetric proliferation - Google Patents

Modulation of asymmetric proliferation Download PDF

Info

Publication number
GB2528604A
GB2528604A GB1518978.0A GB201518978A GB2528604A GB 2528604 A GB2528604 A GB 2528604A GB 201518978 A GB201518978 A GB 201518978A GB 2528604 A GB2528604 A GB 2528604A
Authority
GB
United Kingdom
Prior art keywords
modulation
proliferation
asymmetric
asymmetric proliferation
rate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1518978.0A
Other versions
GB201518978D0 (en
Inventor
Sridhar Ramaswamy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of GB201518978D0 publication Critical patent/GB201518978D0/en
Publication of GB2528604A publication Critical patent/GB2528604A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Provided herein are methods and compositions related to modulation of the rate of asymmetric proliferation of cancer cells. In some embodiments, the methods described herein relate to the treatment of cancer, at least in part, via the modulation of the rate of asymmetric proliferation of cancer cells.
GB1518978.0A 2012-09-21 2013-09-20 Modulation of asymmetric proliferation Withdrawn GB2528604A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261704033P 2012-09-21 2012-09-21
PCT/US2013/060842 WO2014047398A1 (en) 2012-09-21 2013-09-20 Modulation of asymmetric proliferation

Publications (2)

Publication Number Publication Date
GB201518978D0 GB201518978D0 (en) 2015-12-09
GB2528604A true GB2528604A (en) 2016-01-27

Family

ID=50341954

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1518978.0A Withdrawn GB2528604A (en) 2012-09-21 2013-09-20 Modulation of asymmetric proliferation

Country Status (3)

Country Link
EP (1) EP2956132A4 (en)
GB (1) GB2528604A (en)
WO (1) WO2014047398A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016112257A1 (en) * 2015-01-09 2016-07-14 Sridhar Ramaswamy Modulation of asymmetric proliferation
RU2665965C1 (en) * 2017-12-12 2018-09-05 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации" (ФГБУ "НМИЦ радиологии" Минздрава России) Method for screening malignant neoplasms in humans

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2730890C (en) * 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
WO2012177925A1 (en) * 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RES. vol. 68, no. 16, 2008, CHEN et al, 'Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.' , pages 6698 - 6707 *
CANCER RES. vol. 68, no. 22, 2008, XUE QI et al, 'Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability.' , pages 9551 - 9557 *
PNAS vol. 108, no. 31, DEY-GUHA et al, 'Asymmetric cancer cell division regulated by AKT.' , pages 12845 - 12850 *

Also Published As

Publication number Publication date
GB201518978D0 (en) 2015-12-09
EP2956132A1 (en) 2015-12-23
EP2956132A4 (en) 2017-03-01
WO2014047398A1 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
MX366804B (en) R-spondin translocations and methods using the same.
EA201590987A1 (en) CONNECTIONS AND METHODS OF THEIR APPLICATION
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
MX2016004678A (en) Methods and compositions for treating cancer.
MX2015003874A (en) Modulation of ire1.
MX2019008211A (en) Fibrous structures comprising particles and methods for making same.
TW201611843A (en) Methods of treatment with arginine deiminase
MX2014012477A (en) Pyrrolopyrazone inhibitors of tankyrase.
EA201400178A1 (en) BREAST CANCER TREATMENT
PH12018502569A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
IL207310A0 (en) Vaccine compositions
IN2014DN06104A (en)
PH12015501088A1 (en) Dimeric compounds
MX2014010713A (en) Procaspase 3 activation by combination therapy.
AU2013225816A8 (en) Compositions and methods for treating Type III Gaucher Disease
MX364002B (en) Enzyme-activating compounds and compositions.
MX367393B (en) ANTIFUNGAL COMPOSITIONS FOR THE TREATMENT OF SKIN and NAILS.
AU2014249346A8 (en) High purity ovarian cancer stem cells for active autologous immune therapy
MX2014010714A (en) Procaspase combination therapy for glioblastoma.
GB2528604A (en) Modulation of asymmetric proliferation
MX2015000983A (en) Antiperspirant compositions and methods.
MX350868B (en) MEDICAMENTS and METHODS FOR TREATING CANCER.
UA70698U (en) Use of 2-methyl-3-phenylaminomethylquinolin-4-one as antihypoxic, actoprotective and antialcoholic substance
GB2519004A (en) Quinone compounds and their uses for the treatment of cancer
UA69890U (en) Nimelan gel for topical use

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)
S20A Reinstatement of application (sect. 20a/patents act 1977)

Free format text: REQUEST FOR REINSTATEMENT FILED

Effective date: 20151027

S20A Reinstatement of application (sect. 20a/patents act 1977)

Free format text: REQUEST FOR REINSTATEMENT ALLOWED

Effective date: 20151126

WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)